CTIS2023-509774-40-00进行中（未招募）1 期
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer - MK-7339-006
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 672
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Have a histologically or cytologically confirmed diagnosis nonsquamous NSCLC., Male and female participants who are not pregnant and of childbearing potential must follow contraceptive guidance during the treatment period and for 180 days afterwards., Male participants must refrain from donating sperm, and female participants must refrain from donating eggs to others or freeze/store for her own use during the treatment period and for 180 days afterwards., Have stage IV nonsquamous NSCLC., Have confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphomakinase (ALK), or Proto-oncogene tyrosine-protein kinase (ROS1)-directed therapy is not indicated., Have measurable disease based on RECIST 1.1., Have provided archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated Note: Adequacy of biopsy specimen for the above analyses must be confirmed by the central laboratory before the participant can start the induction phase. Submission of another tumor specimen may be required prior to enrolling the participant, if adequate tumor tissue was not provided the first time., Have a life expectancy of at least 3 months., Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)Performance Status assessed within 7 days prior to the administration of studyintervention.8., Have not received prior systemic treatment for their advanced/metastatic NSCLC., Have adequate organ function.
排除标准
- •Has predominantly squamous cell histology NSCLC., Has received prior therapy with olaparib or with any other polyadenosine 5' diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor., Has received prior therapy with an agent directed to programmed cell death ligand 1 (PD-L1), anti PD-L2, or directed to a stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137)., Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML., Has not completed palliative radiotherapy within 7 days of the first dose. Participants must have recovered from all radiation-related toxicities and not require corticosteroids., Has a known additional malignancy that is progressing or has progressed within the past 3years requiring active treatment., Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis., Has a severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients., Has a known hypersensitivity to any components or excipients of cisplatin, carboplatin ,pemetrexed, or olaparib., Has an active autoimmune disease that has required systemic treatment in past 2 years., Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy., Has a known history of human immunodeficiency virus (HIV) infection, a known history of hepatitis B infection, or known active hepatitis C virus infection., Has interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment.
研究者
相似试验
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLCStage IV lung cancer conditionMedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004720-11-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.792
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLCStage IV lung cancer conditionMedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004720-11-ROMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,792
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in 1L ES SCLCExtensive Stage Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004843-22-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc699
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLCMetastatic Squamous Non-small Cell Lung Cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864EUCTR2018-004721-88-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.735
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLCStage IV lung cancer conditionMedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004720-11-DEMerck Sharp & Dohme LLC1,005